Brain Tumor Committee

Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse with Brain Metastasis Velocity >/= 4 Brain Metastases/Year

A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic Oligoastrocytomas

A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade Gliomas

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas

Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme

Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial

Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma

Phase I/II Trial of Concurrent RAD001 (Everolimus) with Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed Glioblastoma

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine with and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma

Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or Without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma

Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone As Treatment for Recurrent Glioblastoma

NCCTG 86-72-51: A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and Oligodendrogliomas

Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas

A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma

A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)